Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery

Launched by THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · May 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to predict if cervical cancer will come back after surgery. Researchers want to see how well they can use a blood test to detect tiny pieces of cancer DNA (called ctDNA) and human papillomavirus (HPV) DNA in the blood. By monitoring these markers, they hope to find out if the cancer is returning earlier than current tests can. This study aims to compare this method with existing ways of checking for cancer recurrence to see which is more effective.

To participate in this trial, women aged 18 and older who have been diagnosed with HPV-positive cervical cancer (stages I-IV) and have not yet received any treatment like surgery or chemotherapy may be eligible. Participants will need to provide blood samples and health information at different times during the study. It’s important to know that this study cannot include pregnant or breastfeeding women, those with serious mental health issues, or anyone currently involved in another clinical trial. If you meet the criteria and are interested, you will learn more about the study and what to expect before deciding to join.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed HPV-positive cervical malignancy at stages I-IV who have not undergone surgery, radiation therapy, or chemotherapy.
• • Patients must be older than 18 years of age.
• • Cervical cancer patients who are eligible for surgery and/or chemoradiotherapy.
• • Estimated life expectancy of more than three months.
• • Understands the study protocol and voluntarily participates in the research by signing the informed consent form.
• • Able to provide specimens and corresponding clinical information at each time point.
• Exclusion Criteria:
• • Patients who are participating in other clinical trials.
• • Pregnant or breastfeeding women.
• • Patients with severe mental illness.
• • Patients who voluntarily withdraw.
• • Patients unable to complete the study protocol.

Trial Officials